Overview

Pembro With Radiation With or Without Olaparib

Status:
Not yet recruiting

Trial end date:
2028-01-02

Target enrollment:

Participant gender:

Summary

This trial will evaluate whether the immune-sensitizing effects of immunotherapy (Pembrolizumab) and radiation with or without a PARP-inhibitor (Olaparib) will increase the effects of immunotherapy in men with high-risk localized prostate cancer.

Phase:

Phase 2

Details

Lead Sponsor:

Zin W Myint

Collaborator:

Merck Sharp & Dohme LLC

Treatments:

Androgens
Olaparib
Pembrolizumab